Oculis Holding AG (OCS) Change in Account Payables (2022 - 2024)
Oculis Holding AG's (OCS) quarterly Change in Account Payables came in at $2.5 million in Q4 2024, up 188.29% year-on-year from $851726.4 in Q1 2024, and up 23.68% quarter-over-quarter from $2.0 million in Q3 2024.
Oculis Holding AG (OCS) Change in Account Payables (2022 - 2024) Analysis & Trends
Oculis Holding AG's Change in Account Payables history runs 3 years deep, the most recent figure standing at $2.5 million for Q4 2024.
- On a quarterly basis, Change in Account Payables rose 188.29% year-over-year to $2.5 million in Q4 2024; TTM through Dec 2024 was -$514032.6, a 200.93% decrease from a year earlier, with the FY2024 full-year figure at -$429673.2, down 202.09% from the prior year.
- Change in Account Payables grew to $2.5 million in Q4 2024 per OCS's latest filing, from $2.0 million in the prior quarter.
- Across five years, Change in Account Payables topped out at $3.5 million in Q4 2022 and bottomed at -$7.4 million in Q1 2024.
- The 3-year median for Change in Account Payables is $2.1 million (2023), against an average of $266803.2.
- Across the five-year window, Change in Account Payables jumped 527.44% in 2023 and plunged 215.5% in 2024, its largest moves.
- Year by year, Change in Account Payables stood at $3.5 million in 2022, then plunged by 180.36% to -$2.8 million in 2023, then soared by 188.29% to $2.5 million in 2024.
- Per Business Quant, the three latest OCS Change in Account Payables figures stand at $2.5 million (Q4 2024), $2.0 million (Q3 2024), and $2.4 million (Q2 2024).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -42.19 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.52 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 35.60 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 16.86 Mn |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 2.46 Mn |
| Dec 31, 2024 | 2.46 Mn |
| Sep 30, 2024 | 1.99 Mn |
| Sep 30, 2024 | 1.99 Mn |
| Jun 30, 2024 | 2.40 Mn |
| Jun 30, 2024 | 2.40 Mn |
| Mar 31, 2024 | -7.36 Mn |
| Mar 31, 2024 | -7.36 Mn |
| Dec 31, 2023 | -2.78 Mn |
| Dec 31, 2023 | -2.78 Mn |
| Sep 30, 2023 | 3.37 Mn |
| Sep 30, 2023 | 3.37 Mn |
| Jun 30, 2023 | 2.25 Mn |
| Jun 30, 2023 | 2.25 Mn |
| Mar 31, 2023 | -2.33 Mn |
| Mar 31, 2023 | -2.33 Mn |
| Dec 31, 2022 | 3.46 Mn |
| Dec 31, 2022 | 3.46 Mn |
| Sep 30, 2022 | -787,982.50 |
| Sep 30, 2022 | -787,982.50 |